title: Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL.
abstract: A new World Health Organization classification was recently proposed. However, classification of peripheral T-cell lymphomas remains to be clarified. Particularly, unspecified type was considered as a heterogeneous category. Here we studied the expressions of chemokine receptors, Th1-associated CXCR3 and CCR5 and Th2-associated marker ST2(L), and activated T-cell receptor OX40/CD134 in 185 patients with nodal T-cell lymphoma, and evaluated the relationship to prognosis. Their expression patterns correlated with the specific subtype of nodal T-cell lymphoma, such as angioimmunoblastic T-cell lymphoma (AILD), anaplastic large cell lymphoma (ALCL), and in peripheral T-cell lymphoma (PTCL), unspecified. In AILD, almost all cases were immunoreactive for OX40/CD134 (96%) and for CXCR3 (89%). In ALCL, all cases were immunonegative for OX40/CD134, and only a few cases (24%) were immunoreactive for CXCR3, whereas almost all cases (94%) were positive for ST2(L). Cases of PTCL, unspecified, were divided into 2 groups; group 1 (cases positive for either ST2(L), CCR5, or CXCR3) tended to show favorable prognosis compared with group 2 (cases negative for ST2(L), CCR5, and CXCR3). Our results indicate that further subtyping of PTCL, unspecified, into groups 1 and 2 could be significant for evaluating prognosis and understanding the functional role of these tumors.
authors.affiliation: Department of Pathology and Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.forename: Kennosuke
authors.initials: K
authors.lastname: Karube
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Suefuji
authors.forename: Makoto
authors.initials: M
authors.lastname: Hamasaki
authors.forename: Chika
authors.initials: C
authors.lastname: Kawasaki
authors.forename: Junji
authors.initials: J
authors.lastname: Suzumiya
authors.forename: Masao
authors.initials: M
authors.lastname: Tomonaga
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kikuchi
mesh_terms: D014408:Biomarkers, Tumor / Q000276:immunology; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000145:classification / Q000276:immunology / Q000473:pathology; D000072179:Interleukin-1 Receptor-Like 1 Protein; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000145:classification / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000276:immunology / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000145:classification / Q000276:immunology / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000145:classification / Q000276:immunology* / Q000473:pathology; D008565:Membrane Proteins / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000145:classification / Q000276:immunology / Q000473:pathology; D011379:Prognosis; D019713:Receptors, CCR5 / Q000378:metabolism; D054367:Receptors, CXCR3; D011956:Receptors, Cell Surface; D019707:Receptors, Chemokine / Q000378:metabolism; D053262:Receptors, OX40; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*
chemical_list: D014408:Biomarkers, Tumor; C515187:CXCR3 protein, human; C079241:IL1RL1 protein, human; D000072179:Interleukin-1 Receptor-Like 1 Protein; D008565:Membrane Proteins; D019713:Receptors, CCR5; D054367:Receptors, CXCR3; D011956:Receptors, Cell Surface; D019707:Receptors, Chemokine; D053262:Receptors, OX40; D018124:Receptors, Tumor Necrosis Factor; C505716:TNFRSF4 protein, human